Importance: The Oregon Psilocybin Services (OPS) program is the first statewide, regulated framework for legal psilocybin in the U.S. Analyzing inaugural-year utilization and safety is essential for informing policy and equity monitoring. Methods: We conducted a descriptive analysis of statewide aggregate data from the OPS Public Dashboard (January 1-Decembe...
Psychedelic and psychedelic-adjacent substances, including 3,4-methylenedioxymethamphetamine (MDMA) and classic serotonergic hallucinogens, are undergoing renewed therapeutic investigation and remain in non-medical use. Inadvertent exposure during early, unrecognized pregnancy is clinically plausible, yet pregnancy-specific safety evidence is limited. To map...
BACKGROUND: Depression and burnout, which are common among healthcare workers, were exacerbated by the COVID-19 pandemic. Mindfulness-Based Stress Reduction (MBSR) and psilocybin have been reported to reduce depressive symptoms, but the efficacy of the combination requires comparison to an active treatment control. We sought to evaluate the safety and prelim...
BACKGROUND: People with HIV (PWH) are disproportionately affected by cigarette use, with a 40 - 70% prevalence rate. Although many express a strong interest in quitting, many PWH who smoke experience lower cessation rates with traditional treatments, in part due to their comorbid anxiety and depressive symptoms. Psilocybin, a classic psychedelic referred to ...
Objective This clinical trial sought to evaluate the safety and preliminary efficacy of psilocybin and MBSR for frontline healthcare providers with symptoms of depression and burnout related to the COVID-19 pandemic. Methods This was a randomized controlled trial that enrolled physicians and nurses with frontline clinical work during the COVID-19 pandemic an...
INTRODUCTION: This study explores the attitudes of psychologists towards psychedelics and psychedelic-assisted therapy (PAT) following the world-first regulatory changes in 2023 in Australia which permitted psilocybin and 3,4-methylenedioxy-methamphetamine (MDMA) to be used in clinical services. METHODS: A purposive sample of 20 Australian psychologists was ...
With its catchy title, historian Benjamin Breen's Tripping on Utopia brings together controversial findings about the human mind, social engineering, and professional responsibility. He delineates the time frame and focus of an inquiry into psychoactive drug research by stating that “Timothy Leary and the Baby Boomers did not usher in the first psychedelic e...
As psychedelic use expands, the number of adverse effects will increase proportionally. New frameworks for monitoring safety outcomes on a population level are required to limit potential harms. Darke et al. characterized 33 lysergic acid diethylamide (LSD) and 10 psilocybin-related deaths in Australia between 2000 and 2023 using the country's sophisticated ...
When Oregon's first psilocybin service center opened in June 2023, allowing those over 21 to take mind-altering mushrooms in a state-licensed facility, the psychedelic revival that had been unfolding over the past two decades entered an important new phase.Psilocybin is still illegal on the federal level. But now, as researchers explore the therapeutic poten...
HISTORY In the early part of twentieth century, these molecules were known as psychotomimetics, meaning that they create a state similar to psychosis. Later on, they were also termed as hallucinogens, but psychedelics usually do not cause hallucinations at a therapeutic dose. The name psychedelics for these substances was first given by Osmond in 1957, meani...
The clinical evaluation of hallucinogens and other small molecules, conventionally termed psychedelics, has seen a dramatic increase in the past 5 years. Several key clinical trials recently demonstrated the potential efficacy of these compounds in treating a variety of mental health conditions including depression, anxiety, and substance use disorders. Conc...
Back to table of contents Previous article Next article ViewpointsFull AccessThe Return of Psychedelics: Still Time to Prevent TragedyStanley N. Caroff, M.D.Stanley N. Caroff, M.D.Published Online:31 Mar 2021https://doi.org/10.1176/appi.pn.2021.4.8AbstractRecently, a movement reviving psychedelic drugs has emerged among physicians, echoed by activists like M...
After a cessation of almost 40 years, there is renewed interest into therapeutic applicationsof the serotonergic psychedelic psilocybin for the treatment of patients with various psychiatric disorders. PubMed was searched for clinical trials into "psilocybin" between 2000 and 2020, complemented by handsearching. Articles were also screened for explanatory mo...
‘Why is psychedelic culture dominated by privileged white men?’ asks historian Mike Jay, referring to a recent study of psychedelic users who are more than likely to be college-educated white males.1 This appears logical, given the figureheads (such as Timothy Leary) who attained cult-like status half a century ago. Many today continue to view psychedelics a...
Antidepressant, atypical antipsychotic, and hallucinogen drugs mediate their actions in part by interactions with the serotonin-2A (5HT2A) receptor. Serotonergic hallucinogen drugs, such as psilocybin, bind most potently as agonists at the 5HT2A receptor, producing profound changes in perception, mood, and cognition. Some of these drugs have been or are curr...
Psilocybin-Research.com
Searchable psilocybin and psilocin bibliometric database.